Table 2.
Cox proportional hazards regression analysis of the risk of all-cause mortality among patients with cervical adenocarcinomas or squamous cell carcinoma and received definitive concurrent chemoradiotherapy
| Crude HR (95% CI) | Adjusted HR* (95% CI) | P value | ||
|---|---|---|---|---|
| Pathologic type | SCC | 1 | 1 | < .0001 |
| adenocarcinoma | 1.93 (1.65-2.26) | 2.10 (1.79-2.46) | ||
| FIGO stage | I | 1 | 1 | < .0001 |
| II | 1.33 (1.09-1.61) | 1.39 (1.14-1.69) | ||
| III | 2.46 (2.01-3.01) | 2.27 (1.85-2.79) | ||
| IV | 4.86 (3.93-6.00) | 3.85 (3.09-4.80) | ||
| EBRT cumulative dose | < 50 Gy | 1 | 1 | .5315 |
| ≥ 50 Gy | 1.20 (1.07-1.34) | 0.96 (0.85-1.09) | ||
| Platinum cumulative dose | < 500 mg | 1 | 1 | .2706 |
| ≥ 500 mg | 0.94 (0.84-1.04) | 0.94 (0.84-1.05) | ||
| IC Brachytherapy dose | No IC Brachytherapy | 1 | 1 | < .0001 |
| < 2500 cGy | 0.35 (0.30-0.40) | 0.45 (0.39-0.53) | ||
| ≥ 2500 cGy | 0.29 (0.25-0.33) | 0.42 (0.36-0.49) | ||
| Age, years | ≥ 70 | 1 | 1 | < .0001 |
| 60-69 | 0.93 (0.80-1.07) | 0.85 (0.74-0.99) | ||
| 50-59 | 0.85 (0.72-1.01) | 0.73 (0.61-0.87) | ||
| 20-49 | 1.35 (1.15-1.58) | 1.10 (0.93-1.30) | ||
| Year of diagnosis | 2007-2009 | 1 | 1 | .0199 |
| 2010-2012 | 0.95 (0.83-1.08) | 0.94 (0.83-1.08) | ||
| 2013-2015 | 0.84 (0.72-0.97) | 0.81 (0.70-0.94) | ||
| CCI score | 0 | 1 | 1 | < .0001 |
| 1 | 1.33 (1.15-1.55) | 1.34 (1.15-1.56) | ||
| ≥ 2 | 1.71 (1.45-2.02) | 1.51 (1.27-1.80) | ||
| Income | < 18,000 NTD | 1 | 1 | .0686 |
| 18,000-22,500 NTD | 0.86 (0.75-0.98) | 0.93 (0.81-1.07) | ||
| 22,500-30,000 NTD | 0.81 (0.67-0.97) | 0.89 (0.74-1.07) | ||
| ≥ 30,000 NTD | 0.75 (0.65-0.88) | 0.81 (0.70-0.95) | ||
| Hospital type | Medical center | 1 | 1 | .7094 |
| others | 1.14 (1.01-1.29) | 0.98 (0.86-1.11) | ||
| Area | North | 1 | 1 | .0657 |
| Middle | 0.97 (0.84-1.12) | 1.08 (0.93-1.25) | ||
| South/East | 1.18 (1.04-1.35) | 1.17 (1.03-1.33) |
*
All variables presented in Table 2 were used in the multivariate analysis.
Gy, gray; SCC, squamous cell carcinoma; ADC, adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; EBRT, external beam radiotherapy; CCI, Charlson comorbidity index; mg, milligrams; HR, hazard ratio; CI, confidence interval; NTD, New Taiwan dollar; IC, intracavitary.